title: Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium.
abstract: Pseudomonas aeruginosa is a major cause of nosocomial infections. This organism shows a remarkable capacity to resist antibiotics, either intrinsically (because of constitutive expression of beta-lactamases and efflux pumps, combined with low permeability of the outer-membrane) or following acquisition of resistance genes (e.g., genes for beta-lactamases, or enzymes inactivating aminoglycosides or modifying their target), over-expression of efflux pumps, decreased expression of porins, or mutations in quinolone targets. Worryingly, these mechanisms are often present simultaneously, thereby conferring multiresistant phenotypes. Susceptibility testing is therefore crucial in clinical practice. Empirical treatment usually involves combination therapy, selected on the basis of known local epidemiology (usually a beta-lactam plus an aminoglycoside or a fluoroquinolone). However, therapy should be simplified as soon as possible, based on susceptibility data and the patient's clinical evolution. Alternative drugs (e.g., colistin) have proven useful against multiresistant strains, but innovative therapeutic options for the future remain scarce, while attempts to develop vaccines have been unsuccessful to date. Among broad-spectrum antibiotics in development, ceftobiprole, sitafloxacin and doripenem show interesting in-vitro activity, although the first two molecules have been evaluated in clinics only against Gram-positive organisms. Doripenem has received a fast track designation from the US Food and Drug Administration for the treatment of nosocomial pneumonia. Pump inhibitors are undergoing phase I trials in cystic fibrosis patients. Therefore, selecting appropriate antibiotics and optimising their use on the basis of pharmacodynamic concepts currently remains the best way of coping with pseudomonal infections.
authors.affiliation: Unité de Pharmacologie cellulaire and moléculaire, Université catholique de Louvain, Bruxelles, Belgium.
authors.forename: N
authors.initials: N
authors.lastname: Mesaros
authors.forename: P
authors.initials: P
authors.lastname: Nordmann
authors.forename: P
authors.initials: P
authors.lastname: Plésiat
authors.forename: M
authors.initials: M
authors.lastname: Roussel-Delvallez
authors.forename: J
authors.initials: J
authors.lastname: Van Eldere
authors.forename: Y
authors.initials: Y
authors.lastname: Glupczynski
authors.forename: Y
authors.initials: Y
authors.lastname: Van Laethem
authors.forename: F
authors.initials: F
authors.lastname: Jacobs
authors.forename: P
authors.initials: P
authors.lastname: Lebecque
authors.forename: A
authors.initials: A
authors.lastname: Malfroot
authors.forename: P M
authors.initials: PM
authors.lastname: Tulkens
authors.forename: F
authors.initials: F
authors.lastname: Van Bambeke
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects*
chemical_list: D000900:Anti-Bacterial Agents